|
 
- 现金
- 28 元
- 精华
- 0
- 帖子
- 8
- 注册时间
- 2011-8-1
- 最后登录
- 2012-1-5
|
本帖最后由 风雨不动 于 2012-4-14 15:05 编辑
REPLICor to disclose new mechanism of action data and interim REP 9AC and REP 9AC’ clinical efficacy data in patients with chronic hepatitis B at the 2011 HEPDART meeting.
December 4-8, 2011, Grand Hyatt Kauai, Koloa, Hawaii
Montreal, Quebec – Friday, November 25, 2011 – REPLICor will disclose new mechanism of action data and updated interim results from its two proof of concept clinical trials with REP 9AC and REP 9AC’ at the 2011 HEPDART meeting to be held from December 4th-8th, 2011. This exclusive meeting is only held every two years and convenes the top experts, opinion leaders and industry analysts. This meeting focuses on advancements in the development of drugs for the treatment of Hepatitis B and Hepatitis C.
REP 9AC and REP 9AC’ represent a new class of antiviral agent (nucleic acid polymers or NAPs) that block the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects contributes to the long term persistence of HBV infection in the liver. REP 9AC and REP 9AC’ rapidly clear HBsAg in the serum of patients infected with HBV and appears to allow these patients to regain effective immunological control over their infection, resulting in sustained virologic responses after only 5-6 months of treatment. REPLICor will present updated clinical efficacy results in a poster presentation running from December 5th-8th.
For the 2011 HEPDART meeting see: http://www.informedhorizons.com/hepdart2011/
(6.合.彩)足球.篮球...各类投注开户下注
第一投注现金网:招代理年薪10万以上:yyu.cc |
-
总评分: 现金 + 11
查看全部评分
|
发表于 2011-12-2 10:33
